Telix Joins Thera4Care to Advance FAP-Targeted Cancer Therapy
Melbourne, Australia, and Indianapolis, Indiana, United States, November 5, 2026 Telix Pharmaceuticals Limited has announced its participation in Thera4Care,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Melbourne, Australia, and Indianapolis, Indiana, United States, November 5, 2026 Telix Pharmaceuticals Limited has announced its participation in Thera4Care,...
